Nothing Special   »   [go: up one dir, main page]

MX2010002248A - Anticuerpos anti-epha2. - Google Patents

Anticuerpos anti-epha2.

Info

Publication number
MX2010002248A
MX2010002248A MX2010002248A MX2010002248A MX2010002248A MX 2010002248 A MX2010002248 A MX 2010002248A MX 2010002248 A MX2010002248 A MX 2010002248A MX 2010002248 A MX2010002248 A MX 2010002248A MX 2010002248 A MX2010002248 A MX 2010002248A
Authority
MX
Mexico
Prior art keywords
hybridoma
antibody
produced
ferm
epha2 antibody
Prior art date
Application number
MX2010002248A
Other languages
English (en)
Inventor
Hasegawajun
Toshiaki Ohtsuka
Atsushi Urano
Junko Yamaguchi
Toshinori Agatsuma
Kaori Nakahara
Takeshi Takizawa
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of MX2010002248A publication Critical patent/MX2010002248A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se describen: un anticuerpo capaz de inhibir la canceración de una célula y/o la proliferación de una célula tumoral; y otros. Se describen específicamente: un anticuerpo que puede reconocer un epítope que puede ser reconocido por un anticuerpo producido por un hibridoma SH 348-1 (FERM BP-10836) o un hibridoma SH 357-1 (FERM BP-10837) ; un anticuerpo producido por un hibridoma SR 348-1 o un hibridoma SH 357-1; un anticuerpo que se produce al humanizar un anticuerpo producido por un hibridoma SH 348-1 o un hibridoma SH 357-1; un agente farmacéutico que comprende cualquiera de los anticuerpos antes mencionados como un ingrediente activo; y otros.
MX2010002248A 2007-08-30 2008-08-29 Anticuerpos anti-epha2. MX2010002248A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007224007 2007-08-30
PCT/JP2008/065486 WO2009028639A1 (ja) 2007-08-30 2008-08-29 抗ｅｐｈａ２抗体

Publications (1)

Publication Number Publication Date
MX2010002248A true MX2010002248A (es) 2010-03-25

Family

ID=40387351

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010002248A MX2010002248A (es) 2007-08-30 2008-08-29 Anticuerpos anti-epha2.

Country Status (26)

Country Link
US (3) US8449882B2 (es)
EP (1) EP2199390B1 (es)
JP (2) JP5312333B2 (es)
KR (4) KR101561416B1 (es)
CN (1) CN101848998B (es)
AU (1) AU2008292352B2 (es)
BR (1) BRPI0816094A2 (es)
CA (1) CA2698146C (es)
CO (1) CO6180469A2 (es)
CY (1) CY1118763T1 (es)
DK (1) DK2199390T3 (es)
ES (1) ES2618316T3 (es)
HR (1) HRP20170407T1 (es)
HU (1) HUE032301T2 (es)
IL (1) IL204211A (es)
LT (1) LT2199390T (es)
MX (1) MX2010002248A (es)
MY (1) MY150621A (es)
NZ (1) NZ583966A (es)
PL (1) PL2199390T3 (es)
PT (1) PT2199390T (es)
RU (1) RU2525133C2 (es)
SI (1) SI2199390T1 (es)
TW (1) TWI443109B (es)
WO (1) WO2009028639A1 (es)
ZA (1) ZA201001340B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8518405B2 (en) 2009-10-08 2013-08-27 The University Of North Carolina At Charlotte Tumor specific antibodies and uses therefor
TW201208701A (en) * 2010-07-12 2012-03-01 Daiichi Sankyo Co Ltd Anti-EPHA2 antibodies and uses thereof
CA2806076A1 (en) 2010-07-22 2012-01-26 The Regents Of The University Of California Anti-tumor antigen antibodies and methods of use
EP2446895A1 (en) * 2010-10-01 2012-05-02 Stemgen S.P.A. EPH receptor expression in tumor stem cells
US9845362B2 (en) 2010-10-08 2017-12-19 The University Of North Carolina At Charlotte Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same
CN110038135B (zh) 2011-03-17 2021-03-05 伯明翰大学 重新定向的免疫治疗
JP5875054B2 (ja) 2013-02-13 2016-03-02 国立大学法人 東京大学 がんの検査方法及び検査用キット
US11554181B2 (en) 2014-09-05 2023-01-17 The University Of North Carolina At Charlotte Tumor specific antibody conjugates and uses therefor
WO2017180530A1 (en) * 2016-04-14 2017-10-19 Academia Sinica Inhibition of scube2, a novel vegfr2 co-receptor, suppresses tumor angiogenesis
WO2017214186A1 (en) * 2016-06-09 2017-12-14 University Of Leicester Monoclonal antibodies, compositions and methods for detecting mucin -like protein (mlp) as a biomarker for ovarian and pancreatic cancer
WO2018135653A1 (ja) 2017-01-23 2018-07-26 学校法人東洋大学 抗ｅｐｈａ２抗体及びこれを用いたｅｐｈａ２の免疫学的検出
US11421032B2 (en) * 2017-05-22 2022-08-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for inhibition of MICA/B shedding
CN109879965B (zh) * 2017-12-06 2022-11-11 北京科立思维生物科技有限公司 抗epha2单链抗体、抗cd3e单链抗体及融合蛋白及其应用
MX2021002107A (es) 2018-09-06 2021-04-28 Daiichi Sankyo Co Ltd Derivado de dinucleotido ciclico novedoso y conjugado de anticuerpo-farmaco del mismo.
AU2019402097A1 (en) 2018-12-17 2021-06-10 Revitope Limited Twin immune cell engager
TW202241454A (zh) 2021-02-01 2022-11-01 日商第一三共股份有限公司 抗體－免疫賦活化劑共軛物之新穎製造方法
WO2022187710A1 (en) * 2021-03-05 2022-09-09 Atreca, Inc. Epha2 antibodies
JPWO2022191313A1 (es) 2021-03-12 2022-09-15
CN117693519A (zh) 2021-05-25 2024-03-12 瓦克斯细胞生物 基于单体拟抗体的嵌合抗原受体和包含其的免疫细胞
JPWO2023167238A1 (es) 2022-03-02 2023-09-07

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992020791A1 (en) 1990-07-10 1992-11-26 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
DE69229477T2 (de) 1991-09-23 1999-12-09 Cambridge Antibody Technology Ltd., Melbourn Methoden zur Herstellung humanisierter Antikörper
DK1024191T3 (da) 1991-12-02 2008-12-08 Medical Res Council Fremstilling af autoantistoffer fremvist på fag-overflader ud fra antistofsegmentbiblioteker
DE69333823T2 (de) 1992-03-24 2006-05-04 Cambridge Antibody Technology Ltd., Melbourn Verfahren zur herstellung von gliedern von spezifischen bindungspaaren
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
CA2177367A1 (en) 1993-12-03 1995-06-08 Andrew David Griffiths Recombinant binding proteins and peptides
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
US6972323B1 (en) 1997-04-01 2005-12-06 Sankyo Company, Limited Anti-Fas antibodies
EP1990409A3 (en) 1999-07-20 2011-05-18 MorphoSys AG Bacteriophage
CA2382655A1 (en) 1999-08-17 2001-02-22 Purdue Research Foundation Antibodies as a cancer diagnostic
AU6784400A (en) * 1999-08-17 2001-03-13 Glaxo Group Limited Treatment of metastatic disease
WO2001074382A1 (en) 2000-03-31 2001-10-11 Purdue Research Foundation Method of treatment using ligand-immunogen conjugates
WO2002000728A2 (en) 2000-06-26 2002-01-03 Gpc Biotech Inc. Methods and compositions for isolating biologically active antibodies
US7101976B1 (en) * 2000-09-12 2006-09-05 Purdue Research Foundation EphA2 monoclonal antibodies and methods of making and using same
CA2953239A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kirin Co., Ltd. Antibody composition-producing cell
WO2002099313A1 (fr) 2001-06-05 2002-12-12 Valeo Dispositif de verrouillage des pignons de transmission
WO2002102973A2 (en) 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
WO2003004057A1 (en) 2001-07-03 2003-01-16 The Hospital For Sick Children Ephrin and eph receptor mediated immune modulation
FR2838742B1 (fr) 2002-04-23 2004-07-09 Inst Nat Sante Rech Med Epitopes t de l'antigene epha2
CA2485548A1 (en) 2002-05-10 2004-02-19 Purdue Research Foundation Epha2 agonistic monoclonal antibodies and methods of use thereof
US20050152899A1 (en) * 2002-05-10 2005-07-14 Kinch Michael S. EphA2 agonistic monoclonal antibodies and methods of use thereof
WO2005051307A2 (en) * 2003-11-20 2005-06-09 Medimmune, Inc. Epha2 agonistic monoclonal antibodies and methods of use thereof
CA2485373A1 (en) * 2002-05-10 2003-11-20 Medimmune, Inc. Epha2 monoclonal antibodies and methods of use thereof
US7662770B2 (en) 2002-05-23 2010-02-16 Purdue Research Foundation Low molecular weight protein tyrosine phosphatase (LMW-PTP) as a diagnostic and therapeutic target
US7326552B1 (en) * 2002-06-21 2008-02-05 Takeda San Diego, Inc. Wild-type kinase domain of human Ephrin receptor A2 (EPHA2) and crystallization thereof
EP1852441B1 (en) 2002-09-24 2012-03-28 The Burnham Institute Agents that modulate EPH receptor activity
CA2499580A1 (en) 2002-09-24 2004-04-08 The Burnham Institute Novel agents that modulate eph receptor activity
NZ541458A (en) 2003-01-07 2006-04-28 Symphogen As Method for manufacturing recombinant polyclonal proteins
AU2003900541A0 (en) 2003-02-07 2003-02-20 Ludwig Institute For Cancer Research Modulation of cell adhesion and tumour cell metastasis
WO2004091510A2 (en) 2003-04-11 2004-10-28 Medimmune, Inc. Recombinant il-9 antibodies and uses thereof
JP2006524693A (ja) 2003-04-11 2006-11-02 メディミューン，インコーポレーテッド ＥｐｈＡ２および非腫瘍性過増殖性細胞障害
WO2004092343A2 (en) 2003-04-11 2004-10-28 Medimmune, Inc. Epha2, hypoproliferative cell disorders and epithelial and endothelial reconstitution
WO2004101764A2 (en) 2003-05-13 2004-11-25 Chiron Corporation Methods of modulating metastasis and skeletal related events resulting from metastases
US20050147593A1 (en) 2003-05-22 2005-07-07 Medimmune, Inc. EphA2, EphA4 and LMW-PTP and methods of treatment of hyperproliferative cell disorders
AU2004242845B2 (en) 2003-05-31 2011-06-02 Amgen Research (Munich) Gmbh Human-anti-human CD3 binding molecules
US20050009033A1 (en) 2003-07-08 2005-01-13 The Regents Of The University Of California Breast cancer genes
WO2005016381A2 (en) 2003-07-21 2005-02-24 Medimmune, Inc. Combination therapy for the treatment and prevention of cancer using epha2, pcdgf, and haah
WO2005012350A2 (en) 2003-07-30 2005-02-10 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Epha2 t-cell epitope agonists and uses therefor
AU2004286198C1 (en) 2003-08-18 2011-02-24 Medimmune, Llc Humanization of antibodies
EP1660534A2 (en) 2003-08-22 2006-05-31 MedImmune, Inc. Humanization of antibodies
CA2542631A1 (en) 2003-10-15 2005-04-28 Medimmune, Inc. Listeria-based epha2 vaccines
DE10354115A1 (de) * 2003-11-19 2005-07-21 Beiersdorf Ag Neue Verwendung von Tensidsystemen zur Verringerung der Schädigung hauteigener Enzyme
WO2005056766A2 (en) 2003-12-04 2005-06-23 Medimmune, Inc. TARGETED DRUG DELIVERY USING EphA2 OR Eph4 BINDING MOIETIES
EP1732580A4 (en) 2003-12-24 2008-01-23 Medimmune Inc EPHA2 VACCINES
EP1745073A2 (en) 2004-05-14 2007-01-24 Receptor Biologix, Inc. Cell surface receptor isoforms and methods of identifying and using the same
US7659374B2 (en) 2004-08-16 2010-02-09 Medimmune, Llc Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
WO2006052409A2 (en) 2004-10-23 2006-05-18 Case Western Reserve University Peptide and small molecule agonists of epha and their uses
EP1814567A4 (en) 2004-10-27 2009-05-06 Medimmune Inc USE OF MODULATORS OF EPHA2 AND EPHRINA1 FOR TREATING AND PREVENTING INFECTIONS
JP2008518022A (ja) 2004-10-27 2008-05-29 メディミューン，インコーポレーテッド 線維症関連疾患を治療するためのＥｐｈＡ２およびエフリンＡ１モジュレーター
WO2006047639A2 (en) 2004-10-27 2006-05-04 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
RU2007133108A (ru) 2005-02-04 2009-03-10 Рэйвен Байотекнолоджиз, Инк. (Us) АНТИТЕЛА, СВЯЗЫВАЮЩИЕСЯ С EphA2, И МЕТОДЫ ИХ ИСПОЛЬЗОВАНИЯ
US7786273B2 (en) 2005-03-14 2010-08-31 Medimmune, Llc Macromolecules comprising a thioether cross-link
KR20080040631A (ko) 2005-05-20 2008-05-08 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 에프린 신호전달과 관련된 질환을 쿠프레독신으로 치료하기위한 조성물과 방법
KR20080080482A (ko) * 2005-09-07 2008-09-04 메디뮨 엘엘씨 독소가 컨쥬게이트된 ｅｐｈ 수용체 항체
US8236772B2 (en) 2005-09-16 2012-08-07 The Board Of Trustees Of The Leland Stanford Junior University Methods of modulating angiogenesis and screening compounds for activity in modulating angiogenesis
EP1968998A4 (en) * 2005-12-21 2010-01-27 Medimmune Llc AFFINITY-OPTIMIZED EPHA2-AGONISTIC ANTIBODIES AND METHODS FOR THEIR USE
WO2007073499A2 (en) 2005-12-21 2007-06-28 Medimmune, Inc. Epha2 bite molecules and uses thereof
BRPI0707679A2 (pt) 2006-02-01 2011-05-10 Tjhe Johns Hopkins University conjugado de polipetÍdeo - Àcido nuclÉico para imunoprofilaxia ou imunoterapia para distérbios neoplÁsticos ou infecciosos
US20080003210A1 (en) * 2006-03-13 2008-01-03 Medimmune, Inc. Non-human primate receptor tyrosine kinases
EP3805269A1 (en) 2006-06-12 2021-04-14 Aptevo Research and Development LLC Single-chain multivalent binding proteins with effector function
KR101528939B1 (ko) 2006-07-18 2015-06-15 사노피 암 치료를 위한 ｅｐｈａ2에 대한 길항제 항체
JP2010511382A (ja) 2006-12-01 2010-04-15 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 癌関連タンパク質キナーゼ
US20100166746A1 (en) 2006-12-04 2010-07-01 Medlmmune Way High potency recombinant antibodies, methods for producing them and use in cancer therapy
WO2009008901A2 (en) 2006-12-15 2009-01-15 Case Western Reserve University Peptide and small molecule agonises of epa and their uses in diseases
US20080199426A1 (en) * 2007-01-11 2008-08-21 Sukhatme Vikas P Methods and compositions for the treatment and diagnosis of vascular inflammatory disorders or endothelial cell disorders
CA2683864A1 (en) 2007-04-13 2008-10-23 Cytopathfinder, Inc. Compound profiling method
WO2008157490A1 (en) 2007-06-18 2008-12-24 Medimmune, Llc Synergistic treatment of cells that express epha2 and erbb2
EP2195342A1 (en) 2007-09-07 2010-06-16 Ablynx N.V. Binding molecules with multiple binding sites, compositions comprising the same and uses thereof
WO2009052830A1 (en) 2007-10-22 2009-04-30 Genmab A/S Novel antibody therapies

Also Published As

Publication number Publication date
JP5312333B2 (ja) 2013-10-09
ZA201001340B (en) 2010-11-24
KR20100057018A (ko) 2010-05-28
US9150657B2 (en) 2015-10-06
CN101848998B (zh) 2016-08-03
BRPI0816094A2 (pt) 2015-03-03
CN101848998A (zh) 2010-09-29
PT2199390T (pt) 2017-03-15
DK2199390T3 (en) 2017-04-03
KR101561417B1 (ko) 2015-10-16
CA2698146C (en) 2016-12-20
KR20150041811A (ko) 2015-04-17
HUE032301T2 (en) 2017-09-28
CO6180469A2 (es) 2010-07-19
JP5688433B2 (ja) 2015-03-25
TW200916480A (en) 2009-04-16
JPWO2009028639A1 (ja) 2010-12-02
EP2199390A1 (en) 2010-06-23
EP2199390B1 (en) 2016-12-21
US8449882B2 (en) 2013-05-28
LT2199390T (lt) 2017-03-10
JP2013198492A (ja) 2013-10-03
KR20150008931A (ko) 2015-01-23
KR101561416B1 (ko) 2015-10-16
AU2008292352B2 (en) 2012-03-08
CY1118763T1 (el) 2017-07-12
RU2525133C2 (ru) 2014-08-10
KR20150041186A (ko) 2015-04-15
MY150621A (en) 2014-02-14
KR101521668B1 (ko) 2015-05-28
EP2199390A4 (en) 2012-12-12
US20100183618A1 (en) 2010-07-22
US20140212439A1 (en) 2014-07-31
NZ583966A (en) 2012-04-27
TWI443109B (zh) 2014-07-01
HRP20170407T1 (hr) 2017-05-05
IL204211A (en) 2016-04-21
AU2008292352A1 (en) 2009-03-05
ES2618316T3 (es) 2017-06-21
CA2698146A1 (en) 2009-03-05
SI2199390T1 (sl) 2017-02-28
PL2199390T3 (pl) 2017-06-30
RU2010111896A (ru) 2011-10-10
WO2009028639A1 (ja) 2009-03-05
KR101561403B1 (ko) 2015-10-16
US20160031987A1 (en) 2016-02-04

Similar Documents

Publication Publication Date Title
MX2010002248A (es) Anticuerpos anti-epha2.
NZ572756A (en) Deimmunized antagonistic anti-human cd40 monoclonal antibody from the ch5d12 antibody
UA94452C2 (ru) Гуманизированные моноклональные антитела к фактору роста гепатоцитов
MX2009004532A (es) Composiciones y metodos para unir esfingosina-1-fosfato.
NZ612647A (en) Anti-bcma antibodies
PH12015500248A1 (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
MX2014001374A (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
MX2014001373A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
NZ604007A (en) Monoclonal antibodies against her2 epitope
MX360671B (es) Composición farmacéutica para el tratamiento y/o prevención del cáncer.
ZA202400108B (en) A group of b7h3 monoclonal antibodies and medical use thereof
MXPA06002890A (es) Anticuerpo antiglipicano 3.
PL1896507T3 (pl) Przeciwciała monoklonalne anty-CD71 i ich zastosowanie do leczenia złośliwych komórek nowotworowych
NZ597023A (en) Monoclonal antibodies that bind to hGM-CSF and medical compositions comprising same
NZ596384A (en) Anti-human cd52 immunoglobulins
CL2012001627A1 (es) Compuestos derivados de 1,3-tiazol-fenilaminopirimidinas, inhibidores de syk; composición farmacéutica; y su uso para el tratamiento de la artritis reumatoide y cancer.
MX2009001829A (es) Anticuerpo especifico prlr y sus usos.
SG159392A1 (en) Humanized anti-cd4 antibody with immunosuppressive properties
UA98332C2 (ru) Гуманизированное антитело к cd44, которое опосредует цитотоксичность в отношении раковых клеток
MX2012002458A (es) Anticuerpos anti-cdcp1 humanizados.
MX2009009816A (es) Anticuerpos monoclonales para el tratamiento del cancer.
NZ597531A (en) Inhibition of tumor metastasis using bv8- or g-csf-antagonists
MY165625A (en) Pharmaceutical composition comprising an anti- cd6 monoclonal antibody useful for the diagnosis and treatment of rheumatoid arthritis
MX2009001341A (es) Anticuerpos especificos de ephb3 y usos de los mismos.
MX2013002718A (es) Composiciones de anticuerpo anti-vegfr-3.

Legal Events

Date Code Title Description
FG Grant or registration